Source: FDA, National Drug Code (US) Revision Year: 2020
CUTAQUIG (Immune Globulin Subcutaneous (Human) - hipp) is a 16.5% immune globulin solution for subcutaneous infusion (IGSC), indicated as replacement therapy for primary humoral immunodeficiency (PI) in adults. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
For subcutaneous use only.
Dose for patients switching to CUTAQUIG from IGIV:
Dose for patients switching to CUTAQUIG from IGSC:
Over time the dose may need to be individualized for each patient, dependent on the pharmacokinetic and clinical response and on the desired IgG trough level. Measure the patient’s serum IgG trough level 2-3 months after switching to CUTAQUIG or after the last CUTAQUIG dose adjustment, in order to determine if a dose adjustment is necessary.
Calculate the difference between the patient’s target serum IgG trough level (in mg/dL) and the IgG trough level obtained during subcutaneous treatment with CUTAQUIG. Find this difference in column 1 of Table 1 and locate the corresponding adjustment amount of CUTAQUIG in mL/administration according to the body weight of the patient.
Use the patient’s clinical response as primary point to consider for any dose adjustment. Additional dose increments may be indicated based on the patient’s clinical response (i.e., infection frequency and severity).
Table 1. Incremental adjustment (mL) of weekly CUTAQUIG dosing based on the calculated difference between actual IgG trough level and the target trough level for the patient*:
Difference from Target Serum IgG Trough Level | Weight-adjusted Dose Increment (mL*) | ||||
---|---|---|---|---|---|
Body Weight | |||||
30 kg | 50 kg | 70 kg | 90 kg | 110 kg | |
50 mg/dl | 3 | 4 | 6 | 8 | 10 |
100 mg/dl | 5 | 9 | 12 | 16 | 19 |
200 mg/dl | 11 | 18 | 25 | 32 | 39 |
300 mg/dl | 16 | 26 | 37 | 47 | 58 |
* Derived from a linear regression model of trough levels and weekly dose per kg body weight.
For example: a patient with body weight of 70 kg is treated weekly and has a trough level of 600 mg/dL, but the target trough level is 900 mg/dL The difference between the actual trough level (600) and the desired trough level (900) is plus 300 mg/dL. Therefore, the recommended increase in the weekly dose would be 37 mL.
Monitor the patient’s clinical response and periodically check trough IgG levels, and repeat dose adjustment as needed.
If a patient has been exposed to measles, it may be prudent to administer a dose of Immune Globulin Intravenous as soon as possible and within 6 days of exposure. A dose of 400 mg/kg should provide a serum level >240 mIU/mL of measles antibodies for at least two weeks.
If a patient is at risk of future measles exposure and receives a dose of less than 245 mg/kg subcutaneously per week, the dose should be increased to 245 mg/kg.
CUTAQUIG is a clear and colorless solution that may turn to slightly opalescent and pale yellow during storage. Do not use the solution if it appears cloudy or contains particulates.
CUTAQUIG is for subcutaneous use only.
Administer CUTAQUIG weekly by a healthcare provider, or by caregiver or self-administered by the patient after appropriate training.
CUTAQUIG may be infused in the following areas: abdomen, thigh, upper arm, and/or upper leg/hip area.
CUTAQUIG is intended for subcutaneous use using an infusion pump and compatible syringe(s).
CUTAQUIG may be infused simultaneously into up to 6 different sites. Infusion sites should be at least 2 inches (5 cm) apart. Rotate infusion sites between subsequent administrations.
Volume:
For patients not already on Immune Globulin Subcutaneous (Human) (IGSC) therapy, the maximum initial volume per injection site should not exceed 25 mL. From the 6th infusion onwards the volume may be gradually increased to a maximum of 40 mL/site as tolerated.
Rate:
Maximum recommended flow rates per hour per infusion site are as follows:
First 6 infusions: 15-20 mL per hour per site.
Subsequent infusions: 25 mL per hour per site as tolerated.
Maximum recommended flow rates per hour for all sites combined:
First 6 infusions: 30 mL per hour for all sites combined.
From infusion number 7 onwards a gradual increase to 50 mL per hour for all sites combined, subsequently to 80 mL per hour for all sites combined, and if tolerated a further gradual increase to up to 100 mL per hour for all sites combined may be possible.
Table 2. Infusion Volumes and Infusion Rates:
Infusion parameters* | Infusion Number | |
---|---|---|
1st-6th | 7th and above | |
Volume (mL/site) | ≤25 | gradually increase to max of 40 |
Rate (mL/hr/site) | ≤20 | 25 |
Rate (mL/hr/all sites combined) | 30 | Gradually increase to 50 mL, then to 80 mL; if well tolerated, use a max of 100 mL |
* As tolerated
CUTAQUIG is for subcutaneous use only.
Follow the administration guidance below and use aseptic technique when administrating CUTAQUIG.
1. Getting ready for infusion:
Figure 1:
2. Checking and opening the vials:
Figure 2:
3. Preparing and filling the syringe:
Figure 3:
4. Preparing the infusion pump and tubing:
Figure 4:
5. Preparing the infusion site(s) and inserting the infusion needle(s):
Figure 5:
Figure 6:
Figure 7:
Figure 8:
6. Checking the infusion:
7. Starting the infusion:
8. Recording the infusion:
9. After infusion is complete:
For self-administration, provide the patient and caregiver with instructions and appropriate training for infusion at home or other appropriate setting. Verify that the patient or caregiver is capable of self-administration using appropriate technique.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.